Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An alveolar soft part sarcoma occurring in adults. The most common site of involvement is the extremity, particularly the deep soft tissues of the thigh.
Features include: Alveolar soft part sarcoma.
ASPSCR1 encodes ASPSCR1 tether for SLC2A4, UBX domain containing (553 aa). Tethering protein that sequesters GLUT4-containing vesicles in the cytoplasm in the absence of insulin. Modulates the amount of GLUT4 that is available at the cell surface. Highest expression in Testis (33.4 TPM) and Pituitary (29.9 TPM).
Alveolar soft part sarcoma is associated with mutations in the ASPSCR1 gene on chromosome 17.
ASPSCR1 is classified as a druggable target (Clinically Actionable, Transcription Factor, and Transporter categories) with score 0.0.
Genetic testing for ASPSCR1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for alveolar soft part sarcoma has been reported in the published literature.
16 clinical trials registered, 7 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 1 PHASE3, 6 PHASE2, 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04332874](https://clinicaltrials.gov/study/NCT04332874) |
Data assembled from 7 of 12 sources · Last updated Nov 3, 2026, 8:45 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg |
PHASE2 |
Memorial Sloan Kettering Cancer Center |
RECRUITING |
[NCT04999761](https://clinicaltrials.gov/study/NCT04999761) | AB122 Platform Study | PHASE1 | Taiho Pharmaceutical Co., Ltd. | RECRUITING |
[NCT03016819](https://clinicaltrials.gov/study/NCT03016819) | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | PHASE3 | Advenchen Laboratories, LLC | RECRUITING |
[NCT05333458](https://clinicaltrials.gov/study/NCT05333458) | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT03967834](https://clinicaltrials.gov/study/NCT03967834) | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | NA | Institut Claudius Regaud | RECRUITING |
96 publications have been identified in PubMed for alveolar soft part sarcoma. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (23%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 29 | 30% |
Research summaries | 22 | 23% |
Testing and diagnosis research | 11 | 11% |
Clinical study results | 11 | 11% |
Laboratory research | 9 | 9% |
Disease patterns and progression | 7 | 7% |
Other research | 6 | 6% |
New treatment approaches | 1 | 1% |
Kojima Y (2026). [PMID: 41242041](https://pubmed.ncbi.nlm.nih.gov/41242041/). *Eur J Cancer*. [Clinical Trial Publication]
Tan H (2026). [PMID: 42051923](https://pubmed.ncbi.nlm.nih.gov/42051923/). *Ther Clin Risk Manag*. [Clinical Trial Publication]
Einarsdottir S (2026). [PMID: 41941698](https://pubmed.ncbi.nlm.nih.gov/41941698/). *Blood Adv*. [Basic Science / Preclinical]
Bilani N (2026). [PMID: 41843220](https://pubmed.ncbi.nlm.nih.gov/41843220/). *Curr Oncol Rep*. [Review / Meta-Analysis]
Zhu B (2026). [PMID: 42241177](https://pubmed.ncbi.nlm.nih.gov/42241177/). *J Cancer Res Ther*. [Case Report / Case Series]
Picozzi F (2026). [PMID: 41630035](https://pubmed.ncbi.nlm.nih.gov/41630035/). *J Transl Med*. [Review / Meta-Analysis]
Kayar K (2026). [PMID: 40501342](https://pubmed.ncbi.nlm.nih.gov/40501342/). *Int J Surg Pathol*. [Case Report / Case Series]
Tan HN (2026). [PMID: 42286316](https://pubmed.ncbi.nlm.nih.gov/42286316/). *NPJ Precis Oncol*. [Basic Science / Preclinical]
Crane JN (2026). [PMID: 41840819](https://pubmed.ncbi.nlm.nih.gov/41840819/). *Pediatr Blood Cancer*. [Diagnostic / Biomarker]
Tamefusa K (2026). [PMID: 41319025](https://pubmed.ncbi.nlm.nih.gov/41319025/). *Jpn J Clin Oncol*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning alveolar soft part sarcoma
Updated Oct 15, 2026
A recent study published in PubMed examines the epidemiology, management, and outcomes of pediatric bone and soft tissue sarcomas in Ireland. The findings contribute to understanding treatment efficacy and patient outcomes in this rare disease population.
A study published on PubMed examines 26 cases of alveolar soft part sarcoma in the female genital tract, providing insights into its clinicopathological features and molecular genetics. This research contributes to the understanding of this rare cancer type.
The SCOPES-II trial protocol outlines a randomized phase II study investigating the efficacy of a short course of preoperative radiotherapy for patients with soft tissue sarcomas in the head and neck, trunk, and extremities. This study aims to improve treatment outcomes for these challenging cancers.
Sapanisertib shows promise for treating rare mTOR-driven disorders, with potential applications in various cancers including bladder and ovarian cancer. Successful late-stage clinical development could unlock orphan-drug incentives and enhance adoption in specialized treatment centers.